Based on these findings, we have proposed that tumor cells could boost their glucose metabolism activity via the glucose-competition/NSUN2 axis, consequently hindering the metabolism and anti-tumor capabilities of CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.